Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    7,029 result(s) found for: cancer. Displaying page 291 of 352.
    «« First « Previous 287  288  289  290  291  292  293  294  295  Next» Last»»
    EudraCT Number: 2020-005106-25 Sponsor Protocol Number: D8241C00001 Start Date*: 2021-11-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced...
    Medical condition: Advanced Haematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007051 Cancer (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002688-77 Sponsor Protocol Number: D9720C00001 Start Date*: 2021-06-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001671-51 Sponsor Protocol Number: SGN35-023 Start Date*: 2016-06-15
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF RITUXIMAB AND BENDAMUSTINE WITH OR WITHOUT BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY CD30-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA
    Medical condition: i) Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma ii) follicular non-Hodgkin lymphoma (NHL) grade 3b
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000144-26 Sponsor Protocol Number: ABI-007-PST-001 Start Date*: 2013-09-17
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary Celgene Corporation
    Full Title: A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory s...
    Medical condition: recurrent or refractory solid tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003990-89 Sponsor Protocol Number: Uni-Koeln-1707 Start Date*: 2015-05-12
    Sponsor Name:University of Cologne
    Full Title: Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –
    Medical condition: Treatment of older patients with newly diagnosed classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-004770-22 Sponsor Protocol Number: TAS-117-201 Start Date*: 2021-04-01
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
    Medical condition: Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10071986 PTEN gene mutation PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004482-14 Sponsor Protocol Number: CEGF816X2101 Start Date*: 2014-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of EGFRmut–TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Temporarily Halted) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004677-20 Sponsor Protocol Number: Gemtax IV Start Date*: 2006-03-17
    Sponsor Name:University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology
    Full Title: Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stag...
    Medical condition: Lung cancer remains the leading cause of cancer-related death in men and has increased its incidence in women over the past decades (protocol page 9). Data from both meta-analysis and clinical tria...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022968-13 Sponsor Protocol Number: ET-B-031-10 Start Date*: 2011-03-16
    Sponsor Name:Pharma Mar, S.A. Sociedad Unipersonal
    Full Title: Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderm...
    Medical condition: Advanced Breast Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000811-12 Sponsor Protocol Number: ST03 Start Date*: 2008-01-31
    Sponsor Name:Medical Research Council Clinical Trials Unit
    Full Title: A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive...
    Medical condition: Patients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma. Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002234-14 Sponsor Protocol Number: OR2805-101 Start Date*: 2023-06-07
    Sponsor Name:OncoResponse, Inc.
    Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
    Medical condition: Solid tumor cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004165-13 Sponsor Protocol Number: IJB-LBC-NEOCHECKRAY-2018 Start Date*: 2019-06-06
    Sponsor Name:Institut Jules Bordet
    Full Title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial
    Medical condition: Luminal B Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003949-42 Sponsor Protocol Number: 208471 Start Date*: 2019-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or i...
    Medical condition: Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003958-67 Sponsor Protocol Number: CAAA405A12302 Start Date*: 2022-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase II/III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging for the detection of PSMA positive tumors using histopathology as a standard of truth (GuideView)
    Medical condition: Untreated high risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001626-56 Sponsor Protocol Number: MK-3475-01A Start Date*: 2020-09-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment Naive Patients with Advanced Non-small Cell Lung C...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011925-14 Sponsor Protocol Number: 1199.37 Start Date*: 2009-08-24
    Sponsor Name:Boehringer Ingelheim
    Full Title: A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients.
    Medical condition: Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st lin...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004231-25 Sponsor Protocol Number: MS201923_0050 Start Date*: 2024-05-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer
    Medical condition: Relapsed platinum resistant small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2020-005822-27 Sponsor Protocol Number: BLU-945-1101 Start Date*: 2021-10-22
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
    Medical condition: EGFR Mutant Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005336-27 Sponsor Protocol Number: FRX106365 Start Date*: 2006-04-21
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The INPACT study (Improving with Nadroparin the Prognosis in Advanced Cancer Treatment) A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in ...
    Medical condition: Advanced malignancies of the lung, pancreas, or prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) SI (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-000394-21 Sponsor Protocol Number: A6301094 Start Date*: 2016-07-20
    Sponsor Name:Pfizer Inc
    Full Title: A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES.
    Medical condition: Acute treatment and secondary prophylaxis of recurrent VTE (venous thromboembolism) in children with or without cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) SI (Completed) PL (Completed) GB (Completed) DE (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 287  288  289  290  291  292  293  294  295  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 17 10:10:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA